Navigation Links
Regeneron Reports Third Quarter 2009 Financial and Operating Results
Date:11/3/2009

nt income was due to lower yields on, and lower balances of, cash and marketable securities in 2009 compared to 2008.

Interest expense decreased to $0.6 million in the third quarter of 2009 from $1.8 million in the comparable quarter of 2008, and to $0.6 million in the first nine months of 2009 from $7.5 million in the same period of 2008. Interest expense in 2009 was attributable to the imputed interest portion of the Company's payments to its landlord to lease newly constructed laboratory and office facilities in Tarrytown, New York, which commenced in the third quarter of 2009. Interest expense in 2008 was attributable to the Company's 5.5 percent Convertible Senior Subordinated Notes; no Notes were outstanding in 2009. During the first nine months of 2008, the Company repurchased $82.5 million in principal amount of its 5.5 percent Convertible Senior Subordinated Notes. In connection with the repurchased notes, the Company recognized a $0.9 million loss on early extinguishment of debt. The remaining $117.5 million of these notes were repaid in full upon their maturity in October 2008.

Income Tax Expense

In the third quarter of 2008, the Company incurred and paid income tax expense, consisting primarily of alternative minimum tax, of $3.1 million, which resulted from the utilization of certain net operating loss carry-forwards for tax purposes that would otherwise have expired over the next several years.

Revision of Previously Issued Financial Statements

The Company has revised its financial statements at December 31, 2008 and for the three and nine months ended September 30, 2008 in connection with the application of authoritative guidance issued by the Financial Accounting Standards Board (FASB) to the Company's December 2006 lease, as amended, of laboratory and office facilities in Tarrytown, New York. The revisions consisted entirely of non-cash adjustments, primarily to the Co
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. Spherix Reports Second Quarter Earnings
7. Tapestry Reports Second Quarter 2007 Results
8. Callisto Reports on Second-Quarter 2007 Milestones
9. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Ga. and RALEIGH, N.C. ... Trial Marketing Communications, LLC (CTMC), and Integrated Clinical ... patient recruitment and retention for clinical trials announce ... Integrated Clinical Trial Marketing Services (i-CTMS). i-CTMS will ... retention services to pharmaceutical, biotechnology and medical device ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and ... the addition of the "MEMS Gyroscopes Analog ... Analysis" report to their offering. ... gyroscopes for tactical grade applications made a lot ... term of reliability. They are now accepted in ...
(Date:12/15/2014)... --Research and Markets , ... announced the addition of the "Cardiac Guidewires - ... offering. Global Guidewires sector is projected to reach ... accounts for nearly 35% (2015) of the ... approximately 25% (2018). Asia-Pacific is ...
Breaking Medicine Technology:Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 3Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 4
... Broadest, Most Comprehensive Survey Provides New Benchmark on MRSA,in Healthcare ... today by APIC: , , WHAT:, ... Methicillin-resistant, Staphylococcus aureus (MRSA), ... in U.S. healthcare facilities., -- MRSA ...
... LEE, N.J.--(BUSINESS WIRE)--Jun 21, 2007 - Neurologix, Inc.,(OTCBB:NRGX) ... issue,of the journal The Lancet of positive results ... disease and the first report of,direct gene transfer ... adult,neurodegenerative disease., The open label Phase 1 study, ...
Cached Medicine Technology:Nationwide MRSA Prevalence Study to Demonstrate Full Scope of,'Superbug' Threat Facing U.S. Healthcare Facilities and Patients 2Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 2Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 3Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 4Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 5Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 6
(Date:12/19/2014)... Dennis Thompson HealthDay ... -- Ebola,s entrance into the United States -- along ... mumps outbreak -- have highlighted cracks in the nation,s ... new health policy report released Thursday. Half of ... respond to infectious disease outbreaks. That was the main ...
(Date:12/19/2014)... 2014 Hands On Mobile Spa, has announced ... Spa On Wheels has been transformed into a utopia for ... world seems to disappear. The Virtual Tour showcases the beauty ... parties, corporate events and more. , The Virtual Tour shows ... which is actually an overhauled Winnebago. Marla Kaplan-Pelle, Director states ...
(Date:12/19/2014)... Wisconsin (PRWEB) December 19, 2014 After ... music performer is again returning to the stage to ... her husband for concert performances, and the successful tour ... was originally announced. , Visit Ticketability.com ... the newly-announced Detroit shows at fair prices. , Music ...
(Date:12/19/2014)... (HealthDay News) -- A new study suggests a possible ... hot flashes and night sweats -- and higher rates ... are common during menopause, affecting about 60 percent of ... after menopause, since they then face a higher risk ... women who exhibit moderate or severe menopausal symptoms are ...
(Date:12/19/2014)... Prostaglandin analogue eye drops -- a common form of ... loss in patients with the eye disease, a new ... of the Moorfields Eye Hospital and UCL Institute of ... people newly diagnosed with open-angle glaucoma -- the most ... leading causes of blindness. About 45 million people ...
Breaking Medicine News(10 mins):Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 2Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 3Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 4Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 2Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 3Health News:Garth Brooks Tickets for Joe Louis Arena: Ticketability.com Becomes a Popular Destination for Discount Tickets for Garth Brooks’ Detroit Concerts Set for February 27-28 2Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Study Supports Benefit of Widely Used Glaucoma Drug 2
... 2 (HealthDay News) -- Babies born to women who smoke ... have a congenital heart defect than are the offspring of ... increased risk ranged from 20 percent to 70 percent, varying ... that obstruct the flow of blood from the right side ...
... long-term alcohol abuse is detrimental to memory function and ... published in Age and Ageing by Oxford ... consumption may decrease the risk of cognitive decline or ... the prevalence of alcohol-related dementia to be about 10% ...
... 18th Conference on Retroviruses and Opportunistic Infections is ... from February 27 through March 2. Day three of ... presentations from scientists supported by the National Institute of ... Institutes of Health. iPrEx Update , ...
... By Amanda Gardner HealthDay Reporter , TUESDAY, March 1 ... announcement Monday that researchers reconfigured immune cells so that they became ... But they say the jury is out on whether the ... is ultimately a cure or what,s called a "functional cure" -- ...
... years are a critical period for addressing weight-related ... University of Illinois at Chicago. Among young children, ... is highest among black and Hispanic children. ... from the U.S. Department of Agriculture to integrate ...
... Eye Institute (NEI) and Food and Drug Administration (FDA) ... endpoints for clinical trials of visual prostheses will be ... visual fields and contrast sensitivity. These assessments may provide ... Today, functional vision outcomes such as ...
Cached Medicine News:Health News:Smoking During Early Pregnancy May Put Baby's Heart at Risk 2Health News:Research suggests alcohol consumption helps stave off dementia 2Health News:Research suggests alcohol consumption helps stave off dementia 3Health News:CROI -- Day 3: Selected highlights of NIH-supported research 2Health News:Gene Therapy Against HIV Not a Proven Cure, Experts Say 2Health News:Gene Therapy Against HIV Not a Proven Cure, Experts Say 3Health News:Gene Therapy Against HIV Not a Proven Cure, Experts Say 4Health News:$1 million USDA grant aims to reduce obesity in preschoolers 2Health News:Visual prostheses: Symposium to explore combining functional endpoints 2
A convenient, rotating standholds up to seven Gilson pipettes (any model) with exceptional stability. Protects your precious pipettes from possible damage or contamination....
... Tracker is an automated solution for scheduling, ... performance testing for all pipettes and liquid ... any balance Supports all gravimetric ... DIN 12650, ISO 9000, NCCLS and GLP ...
... bottom allows easy withdrawal of solution ,• ... ,• Corner pouring lips facilitate pour-out ... for 4, 8, and 12 channel ... withdrawal of practically all of the solution. ...
Reservoir, Low Profile, Single Well, Flat Bottom, 90mL Available Sterile...
Medicine Products: